Introduction
Gene amplification plays an important role in the progression of bladder cancer. More than 30 different genomic loci have been identified that recurrently harbor DNA amplifications (Mitelman, 1994; Kallioniemi et al., 1995; Voorter et al., 1995; Richter et al., 1997 Richter et al., , 1998 Simon et al., 1998; Simon et al., 2000) . Several of these amplifications contain known oncogenes such as HER2 at 17q21, CCND1 at 11q13, MYC at 8q24, EGFR at 7p13, or MDM2 and CDK4 at 12q13-15 (Dalla-Favera et al., 1982; Kondo and Shimizu, 1983; Popescu et al., 1989; Xiong et al., 1992; Reifenberger et al., 1994) . The target genes are unknown for the majority of amplicons, such as 1q21-31, 2q13, 3p22-24, 6p22, 8p11, 8q21, 9p21, 10p13-14, 13q13, 13q31-33, 18p11, 20q, 21p11, 22q11-13, Xp11-13, and Xq21-22.2 (Kallioniemi et al., 1992; Mitelman, 1994; Sauter et al., 1994; Kallioniemi et al., 1995; Voorter et al., 1995; Richter et al., 1997 Richter et al., , 1998 Simon et al., 1998; Richter et al., 1999; Terracciano et al., 1999; Zhao et al., 1999) .
Based on our comparative genomic hybridization (CGH) data of more than 300 bladder carcinomas (Richter et al., , 1998 Simon et al., 1998; Richter et al., 1999; Terracciano et al., 1999; Zhao et al., 1999; Simon et al., 2000) , one of the most common sites of high-level amplification is 6p22, which was present in 10 of 172 advanced-stage tumors of our patients. One of the potential candidate genes at the 6p22 region is E2F3 (Veltman et al., 2003) , which belongs to a family of cell cycle regulatory transcription factors that are controlled by the retinoblastoma tumor suppressor (Lees et al., 1993; Leone et al., 1998; Humbert et al., 2000; Leone et al., 2001; Wu et al., 2001) . Heterodimers of E2F1, E2F2, or E2F3 with DP1 serve as transcriptional activators of genes that promote cell cycling, whereas complexes of E2F/DP with pRb repress transcription and inhibit cell growth (Leone et al., 1998; Nevins, 1998; Trimarchi and Lees, 2002) . Recent reports have indicated that different members of the E2F gene family could play specific and diverse roles in tumorigenesis of various human malignancies. For example, increased copy numbers and overexpression of E2F1 were found in an erythroleukemia cell line (Saito et al., 1995) , and E2F5 was amplified and upregulated in 4.2% of breast cancers (Polanowska et al., 2000) . Decreased expression of E2F1 was to be associated with an increased risk of progression to metastases in bladder cancer (Rabbani et al., 1999) .
Whereas almost all research on E2F3 has been performed in cell line or mice models so far, little is known about the potential role of E2F3 in human cancers. Based on the rate-limiting role of E2F3 for cell proliferation (Humbert et al., 2000) , it is possible that a disturbed regulation of E2F3 could facilitate cell cycle progression and an increased cell proliferation rate. In turn, overexpression of E2F3 could provide a growth advantage to cells exhibiting this alteration, resulting in clonal selection explaining the presence of 6p22 amplifications in advanced-stage tumors. In this study, we applied the tissue microarray (TMA) technology (Kononen et al., 1998) to study E2F3 alterations in urinary bladder cancer. A TMA containing 2317 bladder cancers was used to examine the impact of E2F3 gene copy number changes on the protein expression level, tumor phenotype, and clinical outcome.
Results

Technical aspects
Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed in a blinded way on different TMA sections. Owing to technical reasons, the number of interpretable samples varies between the individual analyses and comparisons.
E2F3 gene amplification
FISH analyses were performed in two steps: prescreening and establishing optimal hybridization conditions was carried out on a mini-TMA containing specimens with 6p22 amplification (as identified by CGH), followed by a large-scale TMA analysis of 2317 clinical specimens. The 6p22-amplification-specific mini-TMA revealed E2F3 amplification in all three cell lines and seven primary tumors that had shown 6p22 amplification by CGH. The average E2F3 copy numbers in these tumors ranged between 7 and 31.
FISH was successful in 875 of 2317 (38%) samples of the large TMA. FISH-related problems (weak hybridization, background, tissue damage) were responsible for about 80%, TMA-linked problems (too few or absence of tumor cells on the TMA spot) were causing about 20% of the noninformative cases. Statistical analysis was limited to 696 tumors, representing the initial biopsies of 696 patients. E2F3 amplification was detected in 49 these 696 tumors. Examples of amplified and nonamplified tumors are shown in Figure 1 . The associations with tumor phenotype are summarized in Table 1 . Within urothelial carcinoma, which is by far the most common bladder cancer subtype, E2F3 amplification was strongly associated with high tumor grade and advanced stage (Po0.0001 each). Most strikingly, E2F3 amplification was absent in pTaG1/G2 tumors (0 of 272), while 11.3% (35 of 311) of the invasively growing urothelial carcinoma (pT1-4) had E2F3 amplification. E2F3 amplification was most frequent in the histological subgroups of muscle invasive urothelial carcinoma (14.3%) and small cell carcinomas (16.7%).
E2F3 expression in bladder tumor cell lines
To estimate the influence of E2F3 amplification on protein expression, Western blot analysis was performed on three amplified (CRL1479, HTB5, HTB9) and two nonamplified bladder tumor cell lines (CRL7882, RT112). All three amplified, but none of the nonamplified cell lines, showed strong E2F3 protein expression (Figure 2 ). number changes (Po0.0001). E2F3 positivity was found in 24 of 34 amplified urothelial carcinomas (70.6%), but in only 82 of 456 (18.0%) nonamplified tumors. This association held also true within the group of 269 pT1-4 urothelial carcinomas that could be analysed by both FISH and IHC (Po0.0001). E2F3 positivity was significantly more frequent in small cell carcinomas (55.6% positive) than in other histologic subtypes (Table 1) . Within urothelial carcinomas, E2F3 expression was linked to advanced stage and high grade (Po0.0001 each). The frequency of E2F3-positive tumors increased from 10% in pTaG1/G2 tumors (49 of 492) to 20.9% in invasively growing pT1-4 urothelial carcinomas (127 of 608).
E2F3 expression and tumor cell proliferation (Ki67 labeling index (LI))
Both gene amplification and protein overexpression were significantly associated with rapid tumor cell proliferation (Po0.0001 each). Analysis of variance (ANOVA) analysis including E2F3 expression/amplification and either tumor stage or grade showed that both E2F3 expression and amplification were independent predictors of rapid tumor cell proliferation (Po0.0001 each). Accordingly, the separate analyses of tumors of identical grades and stages lead to either significant differences in the proliferation between E2F3-negative and -positive tumors or at least to a clear tendency towards a higher Ki67 LI in E2F3-positive tumors (Table 2) .
E2F3 alterations and prognosis
E2F3 expression was associated with poor tumorspecific survival if all patients were included in the analysis (Po0.05,. Figure 3 ). There was no association between E2F3 expression and tumor-specific survival within the subgroup of pT2-4 urothelial carcinomas, or between E2F3 alterations and tumor recurrence or tumor progression among pTa/pT1 tumors. There were too few E2F3-amplified tumors with available survival data to allow statistically meaningful analysis.
Discussion
Previous CGH studies have repeatedly highlighted 6p22 as an amplification site in bladder cancer (Richter et al., 1998 . E2F3, a key gene for G1/S transition (Leone et al., 1998) , has been mapped to 6p22. Studies by array CGH have suggested that E2F3 can be included in the 6p22 amplicon in at least a fraction of bladder tumors (Veltman et al., 2003) . In an attempt to further investigate the importance of E2F3 in primary bladder tumors and in bladder cancer cell lines, we first analysed a mini-TMA composed of 10 tumors with known 6p22 amplification (by CGH). Our finding of an involvement of E2F3 in the 6p22 amplicons of all 10 amplified tumors provided strong evidence for a major role of E2F3 in bladder cancer. Western blot analysis targeting the E2F3 protein showed strong E2F3 overexpression in all amplified cell lines demonstrating a functional relevance of E2F3 amplification. Based on these data, we proceeded to analyse the prevalence and significance of E2F3 amplification/expression in our previously constructed bladder cancer TMA-containing tissues from 2317 different tumors (Richter et al., 2000) . The TMA approach allowed the rapid analysis of more than 800 carcinomas on the DNA and protein level. The findings suggest an important role of E2F3 amplification/overexpression in invasive bladder cancer. A total of 14.3% of muscle invasive bladder cancers showed E2F3 amplification. This makes E2F3 one of the most frequently amplified genes in invasive bladder cancer. Using the same methodological criteria, including FISH protocols, copy number cutoff levels, and TMA resources, we have observed similar frequencies for amplifications of HER2 (14%) and CCND1 (15%) (Zaharieva et al., 2003) in pT2-4 bladder cancer. Remarkably, E2F3 amplification was not found in any of 272 pTaG1/G2 tumors, which is consistent with models suggesting that pTaG1/G2 tumors are genetically stable neoplasias with a much lower likelihood to acquire chromosomal rearrangements than invasively growing tumors (Richter et al., , 1998 Simon et al., 1998; Richter et al., 1999; Zhao et al., 1999; Simon et al., 2001 Simon et al., , 2002 . Recently, chromosomal alterations have been successfully used for the detection of bladder cancer in voided urine cells (Halling et al., 2000; Bubendorf et al., 2001 ) and a commercial FISH test has been approved by the US Food and Drug Administration in 2001. Our data raise the possibility that 6p22 amplification detection could have clinical utility for distinction of invasive and noninvasive bladder tumors in urine cells.
Given the well-known function of E2F3 for S-phase induction (Leone et al., 1998) , it could be expected that E2F3 overexpression exerts an oncogenic function through cell cycle activation. This hypothesis is largely supported by the strong association of E2F3 amplification and expression with tumor cell proliferation (Ki67 LI), which was also found in all large subgroups of tumors with identical grade and stage. Despite this strong link between E2F3 positivity and a high Ki67 LI, no association was found between E2F3 overexpression and prognosis if tumors with comparable tumor stages were examined. This result is not completely unexpected. Although there are studies suggesting a prognostic role of tumor cell proliferation in urinary bladder cancer (Lipponen et al., 1993; Liukkonen et al., 1999) , there are also reports that fail to reproduce these data (Nakopoulou et al., 1998; Pfister et al., 1998) . Our own previous analyses on the same set of carefully staged tumors were unable to show a convincing association of Ki67 LI with prognosis in pTa, pT1, or pT2-4 cancers (Nocito et al., 2001) . Although accelerated cell proliferation is an important prerequisite for tumor growth, it is probably other factors, like invasive growth and the metastatic potential, which are the key determinants for the clinical outcome of neoplastic diseases.
The comparison of E2F3 FISH and IHC data revealed a good but not a perfect correlation. A strong E2F3 expression by IHC was seen in 70% of E2F3-amplified, but in only 18% of nonamplified tumors. These data seem to suggest that E2F3 overexpression is not present in all amplified tumor samples. However, at least some of the discrepant results might be caused by technical reasons. For example, none of the currently commercially available antibodies targeting E2F3 (including that one used in our study) is specifically recommended for IHC on formalin-fixed tissues. It is possible that technical shortcomings of our IHC procedure resulted in a fraction of IHC false-negative samples. Alternatively, our data could indicate that E2F3 is not the (only) amplification target at 6p22. Overexpression of one or several other genes in the same amplicon could be required to drive the growth advantage of amplified cells in 6p22-amplified tumors without E2F3 protein overexpression. There is a growing evidence indicating that the molecular mechanism of gene amplification does not follow the simple one gene-one amplicon concept. Amplification may be a mechanism that is particularly effective to simultaneously overexpress multiple adjacent genes, which may jointly provide a growth advantage to amplified tumor cells. For example, neighboring oncogenes that sometimes undergo coamplification have recently been identified at various genomic regions such as MDM2, GLI, CDK4, and SAS at 12q13-q15 (Reifenberger et al., 1994) or CCND1, EMS1, and INT2 at 11q13 (Hui et al., 1997) .
Only few known genes are known to be located in direct genomic neighborhood of E2F3. A gene of unknown function (GenBank: NM_017774) maps closely centromeric to E2F3. The 579 amino-acid protein contains a domain that is present in several other proteins associated with the translation machinery and in a family of small, uncharacterized archaeal proteins that are predicted to play a role in the regulation of tRNA modification or translation (Anantharaman et al., 2001 ). SOX4, a transcription factor that is a member of the high mobility group (HMG)-box family of DNA binding protein (Farr et al., 1993) , and PRL (the gene encoding Prolactin) map to region between 1 and 2 Mb centromeric to E2F3. Prolactin (PRL) is a protein hormone closely related to growth hormone and mainly secreted in the anterior pituitary lactotrope and the et al., 1990) . However, Northern analysis demonstrated no correlation between amplification and overexpression of these genes in eight cell lines (Bruch et al., 2000) . In summary, E2F3 is regularly included in a bladder cancer amplicon at 6p22. Taking together the known cell cycle activating role of E2F3, its overexpression in amplified tumors, and the association with cell proliferation in vivo, it appears that E2F3 could be an important target gene inside the 6p22 amplification whose overexpression gives growth advantage to amplified tumor cells. This study also demonstrates how a combination of genomic technologies, microarray discovery platforms, and bioinformatics resources can be used to rapidly identify, validate, and characterize target genes for genetic alterations and associate these changes to specific medical conditions.
Materials and methods
CGH
A review of the CGH profiles of 278 primary bladder carcinomas and 20 cell lines previously examined in our laboratory revealed 10 tumors and three cell lines with distinct peaks around 6p22. Examples of CGH profiles are shown in Figure 4 .
Bladder cancer tissue microarray (TMA)
The composition of our bladder cancer TMA containing 2317 formalin-fixed paraffin-embedded tissues from 1853 bladder cancer patients was previously described (Richter et al., 2000; Simon et al., 2002) . Some of the clinical data were updated for this study. All slides of all tumors were reviewed by one pathologist (GS). Tumor stage and grade were defined according to UICC and WHO (Mostofi, 1973; UICC, 1992) . Stage pT1 was defined by presence of both unequivocal tumor invasion of the suburothelial stroma and tumor-free fragments of the muscular bladder wall. Carcinomas with stroma invasion but absence of muscular bladder wall in the biopsy were classified as at least pT1 (pT1-). Clinical data were available from 1123 patients. The medium follow-up period was 42 months (range 1-236 months). Time to recurrence and time to progression (to stage pT2 or higher) were selected as study end points for patients with pTa and pT1 tumors.
Follow-up information was considered complete enough to include a pTa/pT1 cancer patient in the study if cystoscopies had been performed at least at 3, 9, and 15 months, then annually until the end point of this study (recurrence, last control). To include a patient for analyses of time to progression, longer intervals between controls were accepted if the last follow-up control ruled out progression. Recurrences were defined as cystoscopically visible tumors. Tumor progression was defined as the presence of muscle invasion (stage pT2 or higher) in a subsequent biopsy. An overview of the histological and clinical data is given in Table 3 .
FISH
The tissue microarray sections were treated according to the Paraffin Pretreatment Reagent Kit protocol (purchased from Vysis, Downers Grove, IL, USA) before hybridization. FISH was performed with a digoxigenated PAC probe (PAC (Wagner et al., 1997) . Slides were counterstained with 125 ng/ ml 4 0 ,6-diamino-2-phenylindole in an antifade solution. Amplification was defined as presence (in X5% of tumor cells) of at least three times as many E2F3 gene signals than centromere 6 signals.
IHC
Standard indirect immunoperoxidase procedures were used for IHC (ABC-Elite, Vector Laboratories, Burlingame, CA, USA). The monoclonal antibody E2F3 Ab-4 (Lab Vision Corporation, CA, USA) was tested on array sections containing formalin-fixed paraffin-embedded, E2F3-amplified and nonamplified bladder tumors. Optimal staining of the cell nuclei (1 : 100 dilution of primary antibody) could best be achieved after pretreatment in 1 mM EDTA at 991C for 40 min for antigen retrieval. The primary antibody was omitted for negative controls. Diaminobenzidine was used as a chromogen. Some cytoplasmic staining was seen in most tissue spots but only nuclear staining was scored. The IHC staining intensity (scored in a four step scale including 0, 1 þ , 2 þ , and 3 þ ) and the fraction of positive tumor cells was recorded for each tissue spot. Based on these values, a final IHC result was calculated according to the following criteria: Negative: no staining at all, or 1 þ staining intensity in no more than 10% of tumor cells; positive: at least 2 þ staining intensity in more than 10% of tumor cells.
The rabbit monoclonal antibody MIB1 (1 : 800, Dianova, Hamburg, Germany) was employed to detect Ki67 protein (expressed in all cells in G1, S, G2, and M phase) as previously described . Nuclei were considered Ki67 positive if any nuclear staining was seen. The Ki67 LI (percentage of Ki67-positive cells) was determined on each arrayed tumor sample by scoring at least 300 cells each. Tumors with Ki67-negative mitoses were excluded from analyses.
Western analysis
Protein was extracted from about 2 Â 10 6 cells from bladder cancer cell lines CRL1472, HTB5, HTB9, CRL7882, and the RT112 cell line as described (Leone et al., 1998) . In all, 10 mg protein of each sample was subjected to SDS-PAGE on 10% polyacrylamide gels. Proteins were transferred onto PVDF membrane (Bio-Rad, Glattbrugg, Switzerland). The membrane was blocked in TBS (25 mM Tris at pH 7.4, 137 mM NaCl, 2.7 mM KCl) containing 10% skim milk at RT for 2 h. Blots were then incubated with mouse monoclonal E2F3 Ab-4 antibody (5 mg/ml) (Lab Vision, CA, USA), which is directed against the E2F3 full-length protein, in TBS containing 5% skim milk overnight at 41C, and washed subsequently in TBS containing 0.1% Tween 20 for 30 min. Blots were incubated with a second antibody (1 : 2000) (goat anti-mouse IgG, Fc, AP127P; Juro Supply AG, Lucerne, Switzerland) for 1 h at RT, and washed for 30 min. Blots were processed with the ECL system (Amersham Pharmacia Biotech, Dubendorf, Switzerland).
Statistics
All tissue samples on the TMA were utilized for comparisons of amplification and overexpression of E2F3. Only the first biopsy was used for further statistical analyses in patients having more than one tumor on the TMA. Contingency table analysis and Chi-square tests were applied to study the relationship between histology tumor type, grade, stage, and E2F3 expression/amplification. Student's t-tests were employed to examine the associations of the Ki67 LI with E2F3 expression/amplification. ANOVA was utilized to determine the parameters with greatest influence on tumor cell proliferation. Survival curves were plotted according to the Kaplan-Meier method and analysed for statistical differences using a log rank test. Patients with pTa/pT1 tumors were censored at the time of their last clinical control showing no evidence of disease or at the date when cystectomy was performed. Patients with pT2-4 carcinomas were censored at the time of their last clinical control or at the time of death if they died from causes not related to their tumor.
